Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA to study side-effects statement for TV ads

This article was originally published in Scrip

Executive Summary

The US FDAis moving ahead with plans to study whether inclusion of a Medwatch side-effects reporting statement in direct-to-consumer TV commercials detracts from consumer comprehension of important risk information. The study is required under the FDA Amendments Act, which mandated inclusion of a similar statement in print ads. The agency will ask 1,600 subjects to view several TV commercials, including one for a fictitious blood pressure medicine. The placement of two different side-effects reporting statements and the length of time they are presented on-screen will be tested, as will variations in their prominence. The agency said it made changes to the study design based upon feedback from its risk communication advisory panel in May. The advisors recommended studying the statement's impact on consumer understanding of risks and benefits and whether viewers can differentiate between serious adverse events and mild side-effects (Scrip Online, May 19th, 2008).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts